All 1 tracked stories fall under one category: pharma. Faisal Ghiath Sukhtian is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. Khurram Jamil appears in 1 tracked Biotech story from August 16, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Khurram Jamil
All 1 tracked stories fall under one category: pharma. Faisal Ghiath Sukhtian is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. Khurram Jamil appears in 1 tracked Biotech story from August 16, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 7 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Khurram Jamil. Shared-story counts are live from our verified record — not editorial picks.
For biotech and pharma professionals, two Nasdaq micro-cap companies missed earnings, but insider trades reveal divergent internal outlooks: Oncobiologics directors bought $5.16M while Galectin insiders sold $438K.